Target intelligence / Profile preview

OTUD6B antisense RNA 1 (OTUD6B-AS1)

Target
OTUD6B-AS1
Molecular classification
Long noncoding RNA (lncRNA), Antisense RNA, Other (does not fit receptor, enzyme, transporter, or classical drug target categories)
01

Overview

OTUD6B antisense RNA 1 (OTUD6B-AS1) is a long noncoding antisense RNA transcribed from the opposite DNA strand of the OTUD6B gene on chromosome 8, typically found in the nucleus. Functionally, OTUD6B-AS1 regulates gene expression through both transcriptional and post-transcriptional mechanisms, including acting as a molecular sponge for microRNAs. It primarily affects cell proliferation, cell cycle progression (notably by influencing cyclin D1 levels), apoptosis, and signaling pathways such as Wnt/β-catenin. In the context of human disease, OTUD6B-AS1 has emerging roles in cancer biology—cell proliferation, invasion, migration, and prognosis—and has functional impacts in fibrotic diseases like systemic sclerosis. Current evidence does not support OTUD6B-AS1 as a classical drug target, but its expression may be valuable as a molecular biomarker in oncology and related research applications.

Other names
GS1-251I9.4OTUD6B antisense RNA 1 (head to head)OTUD6B-AS1
02

Mechanism of action

Knockdown of OTUD6B-AS1 (antisense oligonucleotides) leads to reduced cell proliferation and increased apoptosis via decreased cyclin D1 expression. Knockdown inhibits the Wnt/β-catenin pathway and impacts EMT-related protein regulation in cancer models. Acts as a competing endogenous RNA (ceRNA), sequestering specific microRNAs (e.g., miR-664b-3p), which regulate downstream oncogenic pathways.

03

Biological functions

Regulation of gene expressionModulation of cell proliferationRegulation of apoptosisModulation of cell cycle (via cyclin D1)Acting as a molecular sponge for microRNAs (e.g., miR-664b-3p)Regulation of Wnt/β-catenin signaling pathwayModulation of epithelial-mesenchymal transition (EMT)
04

Disease associations

Cancer (hepatocellular carcinoma, clear cell renal cell carcinoma)Fibrotic diseases (systemic sclerosis)Other—dysregulation in development, cognitive dysfunction
05

Safety considerations

No clinical safety concerns have been reported, as OTUD6B-AS1 is not a direct therapeutic target. Experimental knockdown with oligonucleotides may alter cell proliferation and apoptosis, but potential off-target or systemic effects in humans are uncharacterized.
06

Biomarkers

OTUD6B-AS1 expression itself is proposed as a diagnostic/prognostic biomarker for tumors such as hepatocellular carcinoma (poor prognosis with high expression), and clear cell renal cell carcinoma (downregulation correlates with poor prognosis)

Beyond the preview

Go deeper on OTUD6B antisense RNA 1 (OTUD6B-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTUD6B antisense RNA 1 (OTUD6B-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call